Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Aggregate amount owned includes 359,195 shares of common stock issuable upon conversion of a loan to Issuer in the principal amount of $1 million and 641,163 shares of common stock issuable upon exercise of warrants outstanding. Such loan is convertible at any time at lender's option at a per share conversion price of $2.784. (2) Percent of class is based on. 13,971,990 fully diluted shares of Common Stock of CalciMedica, Inc. (the "Issuer") outstanding as of May 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Avenue Capital Management II, L.P. is a registered investment adviser and is the manager ("Manager") of Avenue Venture Opportunities Fund II, L.P. (the "Fund"). The general partner of the Fund has delegated all management authority to Manager and therefore, Manager has sole voting and dispositive power over all securities of Issuer held by the Fund but disclaims beneficial ownership thereof except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 13,971,990 shares of Common Stock of Issuer outstanding as of May 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Avenue Venture Opportunities Partners II, LLC ("AVOPII") is the general partner of the Fund. AVOPII has delegated voting and dispositive power over securities held by the Fund to Manager and disclaims beneficial ownership of securities held by the Fund, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 13,971,990 shares of Issuer's common stock outstanding as of May 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) GL Venture Opportunities Partners II, LLC ("GLVOPII") is the managing member of AVOPII, the general partner of the Fund. GLVOPII has no voting or dispositive power over securities held by the Fund and disclaims beneficial ownership of securities held by the Fund, except to the extent of its pecuniary interest, if any, therein. (2) Percent of class is based on 13,971,990 shares of Issuer's common stock outstanding as of May 6, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) Marc Lasry is the beneficial owner of GLVOPII and therefore, is the ultimate beneficial owner of the Fund. Mr. Lasry does not have voting or dispositive power over securities held by the Fund. (2) Percent of class is based on 13,971,990 shares of Issuer's common stock outstanding as of May 6, 2025.


SCHEDULE 13G



 
Avenue Venture Opportunities Fund II, L.P.
 
Signature:/s/ Andrew Schinder
Name/Title:Andrew Schinder POA for Marc Lasry, Member GL Venture Opportunities Partners II LLC, Man. Mbr Avenue Venture Opportunities Partners II LLC, Gen. Ptnr.
Date:05/28/2025
 
Avenue Capital Management II, L.P.
 
Signature:/s/ Andrew Schinder
Name/Title:Andrew Schinder POA for Marc Lasry, Member of Avenue Capital Management II GenPar, LLC, General Partner.
Date:05/28/2025
 
Avenue Venture Opportunities Partners II, LLC
 
Signature:/s/ Andrew Schinder
Name/Title:Andrew Schinder POA for Marc Lasry, Member of GL Venture Opportunities Partners II, LLC, Managing Member
Date:05/28/2025
 
GL Venture Opportunities Partners II, LLC
 
Signature:/s/ Andrew Schinder
Name/Title:Andrew Schinder Attorney-in-Fact for Marc Lasry, Member
Date:05/28/2025
 
Marc Lasry
 
Signature:/s/ Andrew Schinder
Name/Title:Marc Lasry Attorney-in-Fact for Marc Lasry
Date:05/28/2025
Exhibit Information

Exhibit 99.1 Power of Attorney dated January 28, 2019 (filed as Exhibit 99.1 to Schedule 13G on October 3, 2024). https://www.sec.gov/Archives/edgar/data/1792691/000182912624006629/beyondair_ex99-1.htm Exhibit 99.2 Joint Filing Agreement.

Exhibit 99.2

 

AGREEMENT

 

JOINT FILING OF SCHEDULE 13G

 

Each of the undersigned hereby agrees to file jointly the Schedule 13G to which this Agreement is attached, and any amendments to the Schedule 13G (the “Schedule 13G”) filed with respect to the common stock, par value $0.0001 per share, of CalciMedica, Inc., which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

 

It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any future amendments to the Schedule 13G, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning any other party unless such party knows or has reason to believe that such information is inaccurate.

 

It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the Schedule 13G, and any future amendments to the Schedule 13G, filed on behalf of each of the parties hereto.

 

Date: May 28, 2025

 

Avenue Venture Opportunities Fund II, L.P.
     
By: Avenue Venture Opportunities Partners II, LLC  
Its: General Partner  
     
By: GL Venture Opportunities Partners II, LLC  
Its: Managing Member  
     
By: /s/ Andrew Schinder  
Name: Andrew Schinder  
Title: Attorney-in-Fact for Marc Lasry, Member  
     
Avenue Venture Opportunities Partners II, LLC
     
By: GL Venture Opportunities Partners II, LLC  
Its: Managing Member  
     
By: /s/ Andrew Schinder  
Name: Andrew Schinder  
Title: Attorney-in-Fact for Marc Lasry, Member  
     
GL Venture Opportunities Partners II, LLC
     
By: /s/ Andrew Schinder  
Name: Andrew Schinder  
Title: Attorney-in-Fact for Marc Lasry, Member  
     
Avenue Capital Management II, L.P.
     
By: Avenue Capital Management II GenPar, LLC  
Its: General Partner  
     
By: /s/ Andrew Schinder  
Name: Andrew Schinder  
Title: Attorney-in-Fact for Marc Lasry, Member  
     
MARC LASRY
     
By: /s/ Andrew Schinder, Attorney-in-Fact for Marc Lasry